CalciMedica (CALC) insider-affiliated fund buys 248,972 new shares at $0.8033
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CalciMedica, Inc. reported that an investment fund affiliated with director and 10% owner Fred A. Middleton increased its stake. On June 25, 2026, Sanderling Venture Partners VI Co-Investment Fund, L.P. acquired 248,972 shares of common stock at $0.8033 per share. The shares were purchased directly from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent committee of the board. Following this transaction, that fund holds 1,063,272 shares of CalciMedica common stock. Middleton also reports additional direct and indirect holdings, including 36,514 shares held directly and various positions through Sanderling and Golden Triangle entities, while disclaiming beneficial ownership beyond his pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Director-affiliated fund buys additional CalciMedica shares from the company.
An investment fund associated with director and 10% owner Fred A. Middleton acquired 248,972 CalciMedica common shares at $0.8033 per share. The shares were issued by the company under a Securities Purchase Agreement approved by an independent board committee.
This looks like a company-level capital raise with insider participation rather than a secondary trade in the market. After the deal, the co-investment fund holds 1,063,272 shares, and Middleton reports other direct and indirect holdings while disclaiming beneficial ownership except for his pecuniary interest.
Insider Trade Summary
Net Buyer: 248,972 shares ($199,999)
Net Buy
11 txns
Insider
Middleton Fred A
Role
null
Bought
248,972 shs ($200K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 248,972 | $0.8033 | $200K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,063,272 shares (Indirect, By Sanderling Venture Partners VI Co-Investment Fund, L.P.);
Common Stock — 36,514 shares (Direct, null)
Footnotes (1)
- The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI Co-Investment Fund, LP ("SVP VI Co-Investment, LP", together with Sanderling Venture Partners VI, LP., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Securities"). The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Securities"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Key Figures
Shares purchased: 248,972 shares
Purchase price: $0.8033 per share
Fund holdings after purchase: 1,063,272 shares
+3 more
6 metrics
Shares purchased
248,972 shares
Acquired on June 25, 2026 by Sanderling Venture Partners VI Co-Investment Fund, L.P.
Purchase price
$0.8033 per share
Price paid for CalciMedica common stock under Securities Purchase Agreement
Fund holdings after purchase
1,063,272 shares
Total CalciMedica shares held by Sanderling Venture Partners VI Co-Investment Fund, L.P. after transaction
Direct holdings
36,514 shares
CalciMedica common shares reported as held directly by Middleton
Golden Triangle Ventures LLC holdings
8,176 shares
Indirect CalciMedica common stock reported via Golden Triangle Ventures LLC
Largest Sanderling VI position
946,744 shares
CalciMedica common shares held by Sanderling Venture Partners VI, LP
Key Terms
Securities Purchase Agreement, independent committee, beneficially own, beneficial ownership, +1 more
5 terms
Securities Purchase Agreement financial
"The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
independent committee regulatory
"The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board"
An independent committee is a group of individuals within a company who are tasked with reviewing important decisions, such as mergers or acquisitions, without influence from the company's management or major shareholders. Their role is to provide impartial judgment, helping ensure that decisions are made fairly and in the best interest of all stakeholders. For investors, this adds a layer of objectivity and transparency to significant corporate actions.
beneficially own financial
"may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI Co-Investment Fund, LP"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
FAQ
What insider transaction did CalciMedica (CALC) disclose for Fred A. Middleton?
CalciMedica disclosed that an investment fund associated with director and 10% owner Fred A. Middleton acquired 248,972 common shares at $0.8033 per share. The shares were purchased from the company under a Securities Purchase Agreement approved by an independent board committee.
Does Fred A. Middleton report other CalciMedica holdings besides the co-investment fund position?
Yes. Middleton reports 36,514 shares held directly and additional indirect positions through multiple Sanderling and Golden Triangle entities. He may be deemed to beneficially own these securities but expressly disclaims beneficial ownership except to the extent of his pecuniary interest in each entity.